Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
insulin degludec (Tresiba®)
Reference No. 3158
Publication date:
21/10/2016
Appraisal information
insulin degludec (Tresiba®) 100 units/ml solution for injection
insulin degludec (Tresiba®) 200 units/ml solution for injection
insulin degludec (Tresiba®) Unspecified
Company:
Novo Nordisk Ltd
BNF category:
Endocrine system
NMG meeting date:
07/09/2016
AWMSG meeting date:
12/10/2016
Submission Type:
Resubmission
Status:
Recommended with restrictions
Advice No:
2816
Ratification by Welsh Government:
20/10/2016
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Insulin degludec (Tresiba®) is recommended as an option for restricted use within NHS Wales for the treatment of diabetes mellitus in adult patients where treatment with a basal insulin analogue is considered appropriate. Insulin degludec (Tresiba®) is not recommended for use within NHS Wales for the treatment of diabetes mellitus in adolescents and children from the age of 1 year.
Final Appraisal Recommendation (FAR)
Download
insulin degludec (Tresiba) 3158 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
insulin degludec (Tresiba) 3158 ASAR
Clinical Expert (CE) Summary
Download
insulin degludec (Tresiba) 3158 CE Summary
